Advice Stories

Should analysts change their consensus on Crown Crafts (NASDAQ:CRWS) after the latest spike?

  
Crown Crafts is scheduled to announce its earnings today. The stock is currently experiencing an active upward rally. While many of us are getting excited about consumer goods space, we are going to sum up the feasibility of buying Crown. I will address why retail investors ignored this entity since the beginning of the latest economic outlook. [more]
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Crown Crafts has an asset utilization ratio of 140.04 percent. This connotes that the company is making $1.4 for each dollar of assets. An increasing asset utilization means that Crown Crafts is more efficient with each dollar of assets it utilizes for everyday operations.
<div class='circular--portrait-small' style='font-weight: 700;background:#169D0B;color: #E6E6FA;font-size:1.1em;padding-top: 10px;;'>CG</div>
  a day ago at Macroaxis 
By Vlad Skutelnik
Canada Goose Holdings is scheduled to announce its earnings today. The next earnings report is expected on the 11th of November 2020. While some retail investors are becoming indifferent towards consumer cyclical space, we are going to sum up the feasibility of buying Canada as a potential hedging instrument for your current portfolios. We will analyze why Canada Goose investors may still consider a stake in the business given the latest economic outlook.
<div class='circular--portrait-small' style='font-weight: 700;background:#347AFC;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>SM</div>
  2 days ago at Macroaxis 
By Raphi Shpitalnik
SUPER MICRO COMPUTER is scheduled to announce its earnings today. As many baby boomers are still indifferent towards technology space, it makes sense to break down SUPER as a potential position. We will examine the reasons why it is still possible for the company to generate above-average margins given the current economic outlook.
<div class='circular--portrait-small' style='font-weight: 700;background:#800000;color: #F8F8FF;font-size:1.1em;padding-top: 10px;;'>AP</div>
  2 days ago at Macroaxis 
By Gabriel Shpitalnik
Aurinia Pharmaceuticals is scheduled to announce its earnings today. The next earnings report is expected on the 12th of November 2020. While many of us are getting excited about healthcare space, we are going to concentrate on the feasibility of locking in Aurinia. We will cover the possibilities of Aurinia Pharmaceuticals recovering given the current economic outlook.
<div class='circular--portrait-small' style='font-weight: 700;background:#FF0F00;color: #FFFFF0;font-size:1.1em;padding-top: 10px;;'>AT</div>
  2 days ago at Macroaxis 
By Achuva Shats
Agile Therapeutics is scheduled to announce its earnings today. The next earnings report is expected on the 26th of October 2020. As many retail investors are getting excited about healthcare space, it is fair to break down Agile Therapeutics outlook under the current economic conditions. I will address why investors ignored this entity since the beginning of the current economic outlook.
<div class='circular--portrait-small' style='font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:1.1em;padding-top: 10px;;'>AM</div>
  2 days ago at Macroaxis 
By Vlad Skutelnik
Apyx Medical is scheduled to announce its earnings today. The next earnings report is expected on the 9th of November 2020. While many of us are getting excited about healthcare space, we are going to break down the feasibility of acquiring Apyx Medical. We will evaluate if Apyx Medical shares are reasonably priced given the current economic outlook.
<div class='circular--portrait-small' style='font-weight: 700;background:#800000;color: #F8F8FF;font-size:1.1em;padding-top: 10px;;'>MP</div>
  3 days ago at Macroaxis 
By Achuva Shats
Momenta Pharmaceuticals is scheduled to announce its earnings today. The next earnings report is expected on the 29th of October 2020. The stock is undergoing an active downward rally. As many millenniums are getting excited about healthcare space, it is only fair to go over the feasibility of shorting Momenta Pharmaceuticals. We will cover the possibilities of Momenta Pharmaceuticals recovering given the current economic outlook.
<div class='circular--portrait-small' style='font-weight: 700;background:#FF6600;color: #f7f7f7;font-size:1.1em;padding-top: 10px;;'>SY</div>
  3 days ago at Macroaxis 
By Raphi Shpitalnik
Synchronoss Technolo is scheduled to announce its earnings today. The next earnings report is expected on the 2nd of November 2020. As many retail investors are getting excited about technology space, it is fair to sum up Synchronoss outlook under the latest economic conditions. We will analyze why Synchronoss investors may still consider a stake in the business given the latest economic outlook.
<div class='circular--portrait-small' style='font-weight: 700;background:#754DEB;color: #F0FFF0;font-size:1.1em;padding-top: 10px;;'>CW</div>
  few days ago at Macroaxis 
By Achuva Shats
Why analysts lower the firm buy or sell consensus to Buy? Consolidated Water is scheduled to announce its earnings today. The upcoming quarterly report is expected on the 10th of August 2020. Because some of us are getting excited about utilities space, it makes sense to outline Consolidated Water Co in greater detail. We will evaluate why we are still optimistic in anticipation of a recovery. Analysts now have less confidence in Consolidated Water as compared to a month ago. The current buy or sell recommendation of 2 analysts is Buy.
<div class='circular--portrait-small' style='font-weight: 700;background:#169D0B;color: #E6E6FA;font-size:1.1em;padding-top: 10px;;'>AC</div>
  few days ago at Macroaxis 
By Gabriel Shpitalnik
AeroCentury Corp is scheduled to announce its earnings today. Because some of us are getting excited about industrials space, it makes sense to break down AeroCentury Corp in greater detail. We will analyze why AeroCentury Corp investors may still consider a stake in the business given the current current
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page